Fly News Breaks for April 12, 2019
Apr 12, 2019 | 07:37 EDT
Cantor Fitzgerald analyst Matthew Lillis believes Evofem Biosciences' (EVFM) financing agreement for up to $80M, including a strategic investment from PDL BioPharma (PDLI), removes near-term capital concerns. Further, it positions Evofem well to execute other pieces of its long-term financing strategy, which may involve sources of non-dilutive capital that could further benefit shareholders, Lillis tells investors in a research note. He reiterates an Overweight rating on the shares with a $9 price target.
News For EVFM;PDLI From the Last 2 Days
There are no results for your query EVFM;PDLI